Etomoxir Inhibits Splenic Lymphoma
Corresponding Organization :
Other organizations : Inserm, Université Côte d'Azur, Centre de Recherche en Cancérologie de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier, Université de Toulouse, Università della Svizzera italiana, Université de Tours, Université Paris-Est Créteil, Institut Mondor de Recherche Biomédicale, La Ligue Contre le Cancer
Variable analysis
- Treatment with etomoxir (20 mg/kg, IP injection)
- Treatment with vehicle (100 μl PBS/mouse, IP injection)
- Lymphoma engraftment and progression in recipient NSG mice
- Splenic lymphoma cells from plck-GAPDH mice
- Intravenous injection of tumor cells into recipient NSG mice
- Time point for treatment (14 days after tumor cell injection)
- Treatment regimen (3 injections per week)
- Negative control: Treatment with vehicle (100 μl PBS/mouse, IP injection)
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!